Search - tctmd.com

Displaying 1 - 20 of 356

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2025

Michael O'Riordan

June 30, 2025

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

November 2025 Dispatch for the CV Team

Risk Calculators Miss Many Patients Who Present With First MI

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

TCTMD’s Top 10 Most Popular Stories for September 2025

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

TCTMD’s Top 10 Most Popular Stories for June 2025

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content